Last reviewed · How we verify
Pembrolizumab Injection
Pembrolizumab Injection is a Small molecule drug developed by OncXerna Theraputics, Inc.. It is currently FDA-approved. Also known as: Keytruda, MK3475, Doxorubicin or Epirubicin, Cyclophosphamide.
Pembrolizumab Injection, marketed by OncXerna Therapeutics, Inc., is a leading immunotherapy in its class with a key composition patent expiring in 2028. The drug's primary strength lies in its well-established market position and robust clinical trial results. The primary risk is the patent expiry in 2028, which could lead to increased competition from generic versions.
At a glance
| Generic name | Pembrolizumab Injection |
|---|---|
| Also known as | Keytruda, MK3475, Doxorubicin or Epirubicin, Cyclophosphamide, Paclitaxel |
| Sponsor | OncXerna Theraputics, Inc. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma (PHASE2)
- A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007) (PHASE2, PHASE3)
- A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18) (PHASE1)
- A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer (PHASE3)
- NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma (PHASE1)
- Merck IIT: RRP Pembro and Lenvatinib (EARLY_PHASE1)
- A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 (PHASE2, PHASE3)
- A Study of V940/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pembrolizumab Injection CI brief — competitive landscape report
- Pembrolizumab Injection updates RSS · CI watch RSS
- OncXerna Theraputics, Inc. portfolio CI
Frequently asked questions about Pembrolizumab Injection
What is Pembrolizumab Injection?
Who makes Pembrolizumab Injection?
Is Pembrolizumab Injection also known as anything else?
What development phase is Pembrolizumab Injection in?
Related
- Manufacturer: OncXerna Theraputics, Inc. — full pipeline
- Also known as: Keytruda, MK3475, Doxorubicin or Epirubicin, Cyclophosphamide, Paclitaxel
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing